Associations of mortality and sepsis after GLP-1 receptor agonist initiation versus SGLT2 inhibitor or metformin initiation in people with HIV, overweight or obesity, and type 2 diabetes: A target trial emulation
People living with HIV (PLWH) with overweight or obesity and type 2 diabetes (T2D) carry elevated cardiometabolic and infectious morbidity. Comparative effectiveness data for glucagon-like peptide-1 receptor agonists (GLP-1 RAs)against active comparators are scarce in this population. To estimate association...